A monoclonal antibody 4D5, targeting the ECD of the HER2 protein, effectively inhibits the growth of HER2 overexpressing breast tumor cells and enhances their sensitivity to TNF-α (18). The gene discussed is ERBB2; the disease is breast neoplasm.